

EDITORIAL COMMENT

A Novel Technique to Assess Flow-Mediated Vasodilation*

Shafie Fazel, MD,
Richard D. Weisel, MD, FACC,
Subodh Verma, MD, PhD
Toronto, Canada

In this issue of the *Journal*, Dupuis et al. (1) report on a novel technique of assessing flow-mediated vasodilation (FMD) in the brachial artery by scintigraphic hyperemic reactivity (SHR). This technique, which has the potential to be integrated into the resting myocardial perfusion scan, allows noninvasive measurements of endothelial function of the peripheral vasculature.

See page 1473

The hyperemia induced by re-establishing flow in the brachial artery after temporary occlusion increases luminal shear, resulting in the opening of calcium-activated potassium channels and hyperpolarization of the endothelial cells (2). The augmented electric gradient drives calcium entry into the endothelial cell that results in endothelial nitric oxide synthase (eNOS) activation and nitric oxide (NO) elaboration, causing vasodilation (3–8). Endothelial denudation or treatment with a NO synthase inhibitor abolishes FMD. However, blood vessels from mice that lack the eNOS gene still respond to shear stress by dilating, most likely by a prostanoid-dependent pathway (9). Although neuronal regulation of vasomotor tone also has been implicated in FMD, cardiovascular investigators have focused on FMD as an indirect measurement of endothelial function.

The rationale for gauging endothelial function is to gauge the propensity of the vasculature to undergo atherosclerosis (10). The new paradigm of atherosclerosis links oxidative stress, inflammation, thrombosis, and endothelial dysfunction (11,12). Endothelium may be a target that integrates damaging effects of traditional and unknown risk factors and may function as a “barometer” that gauges the magnitude of atherosclerotic forces (13). For instance, known risk factors of atherosclerosis have been associated with endothelial dysfunction, and endothelial dysfunction appears to become manifest before overt atherosclerosis (14,15).

Risk factor stratification is routine in the practice of the cardiovascular physician (16) and forms an important cornerstone of the “Get with the Guidelines” initiative of the American Heart Association. It is clear that aggressive

pharmacologic treatment benefits patients who are in the high-risk category. However, the treatment of choice and the extent of treatment are unclear in patients who have intermediate risk. According to the National Health And Examination Survey (NHANES) III data, 40% to 50% of adults fall into the intermediate-risk group. Further risk stratification with the use of endothelial function assessment could potentially benefit the patients within this large group who have a wide range of risk. Indeed, several trials have examined the utility of vasomotor functions as a prognosticating tool for coronary artery disease (CAD) with modest success (17–25). Albeit not investigated, monitoring endothelial dysfunction may provide another readout to which cardiovascular therapies also may be titrated, as has been suggested for C-reactive protein (CRP) (26).

Although coronary endothelial function, and not necessarily peripheral endothelial function, is the most appropriate point of evaluation, the difficulty in noninvasively monitoring coronary endothelial function prohibits its routine use. Whether endothelial function in the forearm reflects coronary endothelial function is debated. On the one hand, investigators argue that endothelial dysfunction is widespread. Risk factors for coronary atherosclerosis are systemic risk factors and should affect all vascular trees. For instance, the new biomarker of atherosclerosis, systemic CRP (27,28), also partakes in lesion formation by a variety of mechanisms. C-reactive protein leads to endothelial dysfunction by destabilizing eNOS messenger ribonucleic acid and decreasing NO production (29–32). Because these experiments were performed on endothelial cells isolated from human saphenous veins, it also is very likely that CRP exerts similar effects on other endothelial cells both in the peripheral as well as in the coronary circulation. Such evidence is consistent with the assertion that endothelial function in the forearm may relay information about the atherosclerotic propensity within the coronary vasculature.

On the other hand, even in patients with extensive atherosclerosis within the coronary circulation, arteries in the arm frequently appear to be free of atherosclerosis. In fact, the latter observation has led some surgeons to adopt the radial artery as the bypass conduit of choice after the internal mammary arteries (33–36). Furthermore, the endothelial function of the brachial artery does not always correlate with endothelial function of the coronary circulation (37). Thus, the brachial artery reactivity may not always be directly correlated with coronary endothelial function.

Because of the technical challenges of ultrasonographic brachial artery evaluation (38) and the invasiveness of strain-gauge venous impedance plethysmography (39,40), other methods to measure endothelial function in the brachial artery would be a welcome addition. The report by Dupuis et al. (1) presents a noninvasive alternative that may be incorporated into the resting myocardial perfusion scan. There are several issues to discuss concerning the Dupuis et al. (1) report. First, the new technique of SHR has not been

*Editorials published in the *Journal of the American College of Cardiology* reflect the views of the authors and do not necessarily represent the views of *JACC* or the American College of Cardiology.

From the Division of Cardiac Surgery, Toronto General Hospital, Toronto, Canada.

compared with other more accepted methods of FMD measurement such as by ultrasonography. For validation of the proposed new test, direct comparison with a gold standard is helpful. Second, the inpatient variability of SHR is not reported. The precision of a new biomarker must be evaluated to provide the readers with confidence in the proposed new test. Third, the authors reported a sensitivity of 0.7 and specificity of 0.6 in discriminating between patients with CAD versus those without CAD. The modest discriminatory attribute of the test suggests significant limitations in applying the test for further risk stratification. Fourth, the authors compared patients with CAD who were taking multiple medications to patients without CAD. It is well known that several cardiovascular drugs, such as the statins, improve endothelial function (41–43). Thus, the authors may have diminished the discriminatory power of their study. Last, the other arm of each patient served as control. Considering that vasodilators were used exclusively in all patients with CAD, the resultant FMD may have been minimal in comparison with the control arm because of supranormal vasodilation at baseline caused by drugs. These considerations notwithstanding, the ease with which SHR may be incorporated into clinical practice and clinical trials may significantly add to our risk-stratification capability and post-diagnosis monitoring of patients with CAD.

Reprint requests and correspondence: Dr. Subodh Verma, 14EN-215, 200 Elizabeth Street, Toronto, ON, Canada M5G 2C4. E-mail: Subodh.Verma@sympatico.ca.

REFERENCES

- Dupuis J, Arsenault A, Meloche B, Harel F, Stahiloae C, Grégoire J. Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging: a new marker for coronary artery disease. *J Am Coll Cardiol* 2004;44:1473–7.
- Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation* 1995;91:1314–9.
- Cooke JP, Rossitch E Jr., Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. *J Clin Invest* 1991;88:1663–71.
- Miura H, Wachtel RE, Liu Y, et al. Flow-induced dilation of human coronary arterioles: important role of Ca²⁺-activated K⁺ channels. *Circulation* 2001;103:1992–8.
- Olesen SP, Clapham DE, Davies PF. Haemodynamic shear stress activates a K⁺ current in vascular endothelial cells. *Nature* 1988;331:168–70.
- Bank AJ, Sih R, Mullen K, Osayamwen M, Lee PC. Vascular ATP-dependent potassium channels, nitric oxide, and human forearm reactive hyperemia. *Cardiovasc Drugs Ther* 2000;14:23–9.
- Farouque HM, Meredith IT. Relative contribution of vasodilator prostanoids, NO, and KATP channels to human forearm metabolic vasodilation. *Am J Physiol Heart Circ Physiol* 2003;284:H2405–11.
- Farouque HM, Meredith IT. Inhibition of vascular ATP-sensitive K⁺ channels does not affect reactive hyperemia in human forearm. *Am J Physiol Heart Circ Physiol* 2003;284:H711–8.
- Sun D, Huang A, Smith CJ, et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. *Circ Res* 1999;85:288–93.
- Hedblad B, Ogren M, Janzon L, Isacsson SO, Lindell SE. Low pulse-wave amplitude during reactive leg hyperaemia: an independent, early marker for ischaemic heart disease and death. Results from the 21-year follow-up of the prospective cohort study ‘Men born in 1914’, Malmö, Sweden. *J Intern Med* 1994;236:161–8.
- Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. *Circulation* 2003;108:2041–8.
- Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. *Circulation* 2003;108:1917–23.
- Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? *Circulation* 2002;106:640–2.
- Pedrinelli R, Dell’Omo G, Gimelli A, et al. Myocardial and forearm blood flow reserve in mild-moderate essential hypertensive patients. *J Hypertens* 1997;15:667–73.
- Pitkanen OP, Raitakari OT, Ronnema T, et al. Influence of cardiovascular risk status on coronary flow reserve in healthy young men. *Am J Cardiol* 1997;79:1690–2.
- Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837–47.
- Gokce N, Keaney JF Jr., Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. *Circulation* 2002;105:1567–72.
- Gokce N, Keaney JF Jr., Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. *J Am Coll Cardiol* 2003;41:1769–75.
- Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. *Circulation* 2002;106:653–8.
- Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 2001;104:2673–8.
- Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. *Am J Cardiol* 2000;86:207–10.
- Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. *Circulation* 2001;104:191–6.
- Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 2000;101:1899–906.
- Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 2000;101:948–54.
- Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr., Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. *Circulation* 2003;107:2805–9.
- Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med* 2001;344:1959–65.
- Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;342:836–43.
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002;347:1557–65.
- Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. *Circulation* 2002;106:913–9.
- Verma S, Yeh ET. C-reactive protein and atherothrombosis—beyond a biomarker: an actual partaker of lesion formation. *Am J Physiol Regul Integr Comp Physiol* 2003;285:R1253–6.
- Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation* 2003;107:1783–90.
- Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. *Circulation* 2002;105:1890–6.
- Borger MA, Cohen G, Buth KJ, et al. Multiple arterial grafts. Radial versus right internal thoracic arteries. *Circulation* 1998;98:II7–13.
- Fazel S, Mallidi HR, Pelletier MP, et al. Radial artery use is safe in patients with moderate to severe left ventricular dysfunction. *Ann Thorac Surg* 2003;75:1414–21.

35. Femes SE, Christakis GT, Del Rizzo DF, Musiani A, Mallidi H, Goldman BS. The technique of radial artery bypass grafting and early clinical results. *J Card Surg* 1995;10:537–44.
36. Femes SE. Multicenter Radial Artery Patency Study (RAPS). Study design. *Control Clin Trials* 2000;21:397–413.
37. Bottcher M, Madsen MM, Refsgaard J, et al. Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve. *Circulation* 2001;103:1109–14.
38. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;39:257–65.
39. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. *J Am Coll Cardiol* 2001;37:1344–50.
40. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. *Circulation* 2001;104:2879–82.
41. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation* 1997;95:1126–31.
42. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. *Lancet* 1995;346:467–71.
43. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. *N Engl J Med* 1995;332:481–7.